Computational tool for the early screening of monoclonal antibodies for their viscosities

mAbs

Volumn 8, Issue 1, 2016, Pages 43-48

  Agrawal, Neeraj J ^a   Helk, Bernhard ^b   Kumar, Sandeep ^c   Mody, Neil ^d   Sathish, Hasige A ^d   Samra, Hardeep S ^d   Buck, Patrick M ^c   Li, Li ^c   Trout, Bernhardt L ^a  

^a Massachusetts Institute of Technology   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c PFIZER INC   (United States)

^d MEDIMMUNE   (United States)

Author keywords

Antibodies; Biotherapeutics; Computer simulation; Spatial charge map; Viscosity

Indexed keywords

IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY;

ARTICLE; COMPUTER SIMULATION; HIGH THROUGHPUT SCREENING; MATHEMATICAL PARAMETERS; MOLECULAR DOCKING; PH MEASUREMENT; PROTEIN STRUCTURE; SCORING SYSTEM; SEQUENCE ANALYSIS; SOLUBILITY; STRUCTURAL BIOINFORMATICS; VISCOMETRY; VISCOSITY; CHEMISTRY; MOLECULAR MODEL; PROTEIN TERTIARY STRUCTURE; SOFTWARE;

ANTIBODIES, MONOCLONAL; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; SOFTWARE; VISCOSITY;

EID: 84964556520     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1099773     Document Type: Article

References (19)

1. Chaudhri A, Zarraga IE, Yadav S, Patapoff TW, Shire SJ, Voth GA. The role of amino acid sequence in the self-association of therapeutic monoclonal antibodies: insights from coarse-grained modeling. J Phys Chem B 2013; 117:1269-79; PMID:23316912; http://dx.doi. org/10.1021/jp3108396
2. Liu J, Nguyen MD, Andya JD, Shire SJ. Reversible selfassociation increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J Pharm Sci 2005; 94:1928-40; PMID:16052543; http://dx.doi. org/10.1002/jps.20347
3. Yadav S, Laue TM, Kalonia DS, Singh SN, Shire SJ. The influence of charge distribution on self-association and viscosity behavior of monoclonal antibody solutions. Mol Pharm 2012; 9:791-802; PMID:22352470; http://dx. doi.org/10.1021/mp200566k
4. Yadav S, Shire SJ, Kalonia DS. Factors affecting the viscosity in high concentration solutions of different monoclonal antibodies. J Pharm Sci 2010; 99:4812-29; PMID:20821382; http://dx.doi.org/10.1002/jps.22190
5. Yadav S, Shire SJ, Kalonia DS. Viscosity analysis of high concentration bovine serum albumin aqueous solutions. Pharm Res 2011; 28:1973-83; PMID:21491149; http://dx.doi.org/10.1007/s11095-011-0424-7
6. Nichols P, Li L, Kumar S, Buck PM, Singh SK, Goswami S, Balthazor B, Conley TR, Sek D, Allen MJ. Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions. MAbs 2015; 7:212-30; PMID:25559441; http://dx.doi.org/10.4161/19420862.2014.985504
7. Li L, Kumar S, Buck PM, Burns C, Lavoie J, Singh SK, Warne NW, Nichols P, Luksha N, Boardman D. Concentration dependent viscosity of monoclonal antibody solutions: explaining experimental behavior in terms of molecular properties. Pharm Res 2014; 31:3161-78; PMID:24906598; http://dx.doi.org/10.1007/s11095-014-1409-0
8. Yadav S, Liu J, Shire SJ, Kalonia DS. Specific interactions in high concentration antibody solutions resulting in high viscosity. J Pharm Sci 2010; 99:1152-68; PMID:19705420; http://dx.doi.org/10.1002/jps.21898
9. Sharma VK, Patapoff TW, Kabakoff B, Pai S, Hilario E, Zhang B, Li C, Borisov O, Kelley RF, Chorny I, et al. In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability. ProcNatl Acad Sci U S A 2014; 111:18601-6; PMID:25512516; http://dx.doi.org/10.1073/pnas.1421779112
10. Salinas BA, Sathish HA, Bishop SM, Harn N, Carpenter JF, Randolph TW. Understanding and modulating opalescence and viscosity in a monoclonal antibody formulation. J Pharm Sci 2010; 99:82-93; PMID:19475558; http://dx.doi.org/10.1002/jps.21797
11. Buck PM, Chaudhri A, Kumar S, Singh SK. Highly viscous antibody solutions are a consequence of network formation caused by domain-domain electrostatic complementarities: insights from coarse-grained simulations. Mol Pharm 2015; 12:127-39; PMID:25383990; http://dx.doi.org/10.1021/mp500485w
12. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci U S A 2009; 106:11937-42; PMID:19571001; http://dx.doi.org/10.1073/pnas.0904191106
13. Lauer TM, Agrawal NJ, Chennamsetty N, Egodage K, Helk B, Trout BL. Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. J Pharm Sci 2012; 101:102-15; PMID:21935950; http://dx.doi.org/10.1002/jps.22758
14. Dillon TM, Ricci MS, Vezina C, Flynn GC, Liu YD, Rehder DS, Plant M, Henkle B, Li Y, Deechongkit S, et al. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem 2008; 283:16206-15; PMID:18339626; http://dx.doi.org/10.1074/jbc.M709988200
15. Whitelegg NR, Rees AR. WAM: an improved algorithm for modelling antibodies on the WEB. Protein Eng 2000; 13:819-24; PMID:11239080; http://dx.doi. org/10.1093/protein/13.12.819
16. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 1997; 18:2714-23; PMID:9504803; http://dx.doi.org/10.1002/elps. 1150181505
17. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996; 14:33-&; PMID:8744570; http://dx.doi.org/10.1016/0263-7855(96)00018-5
18. MacKerell AD, Bashford D, Bellott M, Dunbrack RL, Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S, et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 1998; 102:3586-616; PMID:24889800; http://dx.doi.org/10.1021/jp973084f
19. Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281:23514-24; PMID:16793771; http://dx.doi.org/10.1074/jbc.M604292200